#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Inclusion body myositis Mastocytosis Bladder cancer Behcet's syndrome Barth syndrome Scedosporium infection Chronic lymphocytic leukaemia recurrent Acute myeloid leukaemia Congenital absence of bile ducts Pleural mesothelioma Vulval cancer recurrent Wiskott-Aldrich syndrome Stress cardiomyopathy Salivary gland cancer Cardiac sarcoidosis More trials…

    Learn about Rare Diseases

    Haemophagocytic lymphohistiocytosis – Diagnostics Phenylketonuria – Life with Disease Cystic fibrosis lung – Basic Information Gaucher’s disease type III – Treatment Burkitt’s lymphoma – Diagnostics Niemann-Pick disease Langerhans’ cell histiocytosis Mitochondrial myopathy – Diagnostics Sjogren’s syndrome – Trials in Disease Glycogen storage disease type II – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Piflufolastat (18F) Gad20-209-Fsp-A1 Nimorazole Tasipimidine Tradipitant XMAB942 Aminocaproic Acid LYSERGIDE Almagate CANNABINOL Livmoniplimab Ambrosia Artemisiifolia (302) Teriparatide CICLOPIROX OSIMERTINIB MESYLATE Dalteparin Sodium Apl-101 Ampicillin LY3372993 Capivasertib More therapies…

    Learn about Your Condition

    Anal cancer stage III Arthralgia Arteriovenous graft thrombosis Langerhans' cell histiocytosis Chronic hepatitis C Frontotemporal dementia Right ventricular dysfunction Pneumothorax Neutropenia Hypertonic bladder Angiosarcoma recurrent Osteoporosis Hyperhidrosis Renal transplant Corneal graft rejection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General University Hospital Of Larissa

General University Hospital Of Larissa

P. O. Box 1425, Larissa, 411 10, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • A study comparing the effectiveness of brimonidine tartrate and timolol eye drops versus a standard combination in patients with glaucoma or ocular hypertension

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Brimonidine Tartrate
    • Timolol
    • Timolol Maleate
    Greece

  • A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    • Paclitaxel Albumin-Bound
    Czechia France Germany Greece Hungary Italy +2

  • A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

    Recruiting

    2 1
    Investigated Diseases:
    • Bronchiectasis
    Investigated Drugs:
    • AZD0292
    Belgium Denmark France Germany Greece Italy +2

  • A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • Tenecteplase
    Bulgaria Greece Hungary Norway Romania Spain

  • Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Sotorasib
    • Panitumumab
    • Irinotecan Hydrochloride Trihydrate
    Austria Belgium Bulgaria Czechia Denmark Estonia +12

  • A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • Remibrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +19

  • A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Interstitial lung disease
    Investigated Drugs:
    • Belimumab
    Belgium France Germany Greece Italy The Netherlands +1

  • A study to evaluate the safety of dazodalibep in patients with Sjögren’s Syndrome over a long period of time

    Recruiting

    3 1 1
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium Bulgaria Croatia Czechia France +7
Previous Page
1 2 3 4 … 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!